

Portal Hypertensive Gastropathy and Colopathy

Nathalie H. Urrunaga, MD, MS^a, Don C. Rockey, MD^{b,*}

KEYWORDS

• Cirrhosis • Hemorrhage • Bleeding • Pressure • Portal hypertension

KEY POINTS

- PHG and PHC can cause acute and/or chronic gastrointestinal bleeding.
- Diagnosis for both is endoscopic.
- The specific management of PHG and PHC depends on the clinical presentation.
- For acute bleeding, hemodynamic stabilization with intravenous (IV) fluids, IV antibiotics, and blood transfusion as needed should be begun immediately. This should be followed by IV pharmacologic therapy to decrease portal pressure, and subsequently by nonselective β -blockers.
- In patients with chronic bleeding, therapy with β -blockers and iron replacement is recommended. The role of TIPS is controversial.
- Patients with refractory bleeding should be managed on an individual basis.

INTRODUCTION

The most common cause of portal hypertension is liver cirrhosis, which causes so-called intrahepatic or sinusoidal portal hypertension. Other disorders including presinusoidal and postsinusoidal diseases (ie, portal vein thrombosis, schistosomiasis, veno-occlusive disease, cardiac failure) may also cause increased portal pressure. Portal hypertension likely causes hemodynamic and mucosal changes in the entire gastrointestinal (GI) tract. This article focuses on the pathogenesis, diagnosis, and treatment of portal hypertensive gastropathy (PHG) and colopathy (PHC) (**Table 1**).

The cause of PHG and PHC is incompletely understood. However, available data indicate that portal hypertension is a critical component. It has been recognized

N.H. Urrunaga was supported by the NIH (Research Grant T32 DK 067872).

Disclosure of Conflicts: The authors certify that they have no financial arrangements (eg, consultancies, stock ownership, equity interests, patent-licensing arrangements, research support, major honoraria, and so forth).

^a Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, 22 S. Greene Street, N3W156, Baltimore, MD 21201, USA; ^b Department of Internal Medicine, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 803, Charleston, SC 29425, USA

* Corresponding author.

E-mail address: rockey@muscc.edu

Clin Liver Dis 18 (2014) 389–406
<http://dx.doi.org/10.1016/j.cld.2014.01.008>

liver.theclinics.com

1089-3261/14/\$ – see front matter © 2014 Elsevier Inc. All rights reserved.

Features	Portal Hypertensive Gastropathy	Portal Hypertensive Colopathy
Endoscopic characteristics	Mosaic pattern and red spots	Mosaic pattern and red spots, sometimes, vascular ectasia appearance
Pathology	Dilated capillaries and venules, no inflammation	Edema and capillary dilatation, lymphocytes and plasma cells, in lamina propria
Treatment	Iron-replacement therapy Transfusions Portal pressure-reducing agents	^a Iron-replacement therapy Transfusions Portal pressure-reducing agents
Salvage treatment	TIPS/shunt surgery APC Liver transplantation	TIPS/shunt surgery APC Liver transplantation

Current practice is based on case and case series reports.

^a There are insufficient data for standard recommendations in PHC bleeding.

that mucosal changes in the gastric mucosa of patients with portal hypertension were different pathologically from inflammatory gastritis; this led to the early description “congestive gastropathy.”¹ The primary pathologic change was characterized by vascular ectasia. PHG is recognized endoscopically as a mosaic-like pattern called snakeskin mucosa with or without red spots.² Additionally, the terms portal hypertensive enteropathy^{3,4} and PHC^{5,6} were created to describe similar changes in the small bowel and colonic mucosa, respectively. PHC is characterized by erythema of the colonic mucosa, vascular lesions including cherry-red spots, telangiectasias, or angiodysplasia-like lesions.

PHG and PHC are important clinically because they may lead to chronic and/or acute GI bleeding. Both disorders are often confused with other diseases that can present similarly. Careful investigation is essential to accurately delineate the proper diagnostic needs and to start specific treatment.

PORTAL HYPERTENSIVE GASTROPATHY

Epidemiology

The prevalence of PHG in patients with cirrhosis varies from 20% to 98%.^{2,7–12} This variation seems to be caused by several factors, including the study of different populations and variable patient selection, different interpretation of endoscopic lesions, and lack of uniform diagnostic criteria and classification.

Some studies have demonstrated a higher prevalence of PHG in patients with advanced liver disease, esophageal varices, or history of sclerotherapy or ligation for esophageal varices.^{7,9,10} In general, the available data suggest that PHG is often associated with more severe portal hypertension.¹³ It has also been suggested that the prevalence of PHG increases as esophageal varices are obliterated,² although this point is controversial.

Clinical Findings

Most patients with PHG are asymptomatic, but a significant number of patients exhibit symptoms related to chronic GI bleeding and chronic blood loss/iron deficiency anemia. A smaller proportion of patients exhibit evidence of active GI bleeding.

Download English Version:

<https://daneshyari.com/en/article/3461059>

Download Persian Version:

<https://daneshyari.com/article/3461059>

[Daneshyari.com](https://daneshyari.com)